The generic drugs market in the Midwest grew by 6.45% in 2025, surpassing the national average and consolidating the region as a strategic hub for the pharmaceutical sector. 87.2 million units were sold, equivalent to 7.58% of the entire volume sold in the country in the period - which totaled 1.1 billion units.
The state of Goiás was the highlight, accounting for 51.25% of regional sales, with 44.7 million units and growth of 7.19% over 2024. Next came Mato Grosso (15.8 million units, up 6.37%), the Federal District (15.5 million units, up 3.85%) and Mato Grosso do Sul, which recorded the highest proportional growth: 7.36%, with 11.1 million units sold.
According to Tiago de Moraes Vicente, CEO of PróGenéricos, the result reaffirms the importance of generics in democratizing access to healthcare:
"The significant growth in the Midwest demonstrates that generic drugs continue to play a greater role in giving the population access to quality treatments at more affordable prices. States like Goiás and Mato Grosso do Sul have made progress above the regional average, reflecting the consolidation of this successful public policy."
The executive also points out that the regional progress is in line with the movement seen in the rest of the country:
"The fact that the region accounts for 7.58% of the entire volume of generics sold in Brazil reinforces its weight in the market and the potential for expansion. This result is the fruit of industry, pharmacies and health professionals working together to inform and raise awareness about the efficacy and safety of generics."
It should be noted that the region has a strategic production center for the pharmaceutical industry: the Anápolis Agroindustrial District (DAIA), in Goiás. Considered one of the largest pharmaceutical industrial complexes in Latin America, the DAIA is home to important national and multinational companies in the sector, responsible for a large part of the production of generic drugs distributed throughout the country.
"The presence of DAIA and other pharmaceutical plants in the Midwest strengthens Brazil's production autonomy and guarantees more agility in the distribution of medicines. This infrastructure plays an essential role in sustaining the growth of the category," says the president of PróGenéricos.
cc: pexels-karolina-grabowska-4210654